Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 15,824 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Product Clear all

Conditions: Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer, Prostate Cancer
Interventions: MDX-1106; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Baltimore, Maryland • Detroit, Michigan • St Louis, Missouri + 1 more

Conditions: Rheumatoid Arthritis
Interventions: PF-04171327, prednisone, prednisone, placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 14
States / cities: Tucson, Arizona • San Leandro, California • Newark, Delaware + 9 more

Conditions: HER2-positive Early-stage Breast Cancer
Interventions: Trastuzumab, Pertuzumab, Docetaxel, Carboplatin; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Elizabeth, New Jersey • Hamilton, New Jersey • Long Branch, New Jersey + 4 more

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Nelfinavir mesylate, Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 2
States / cities: Birmingham, Alabama • San Francisco, California

Conditions: Cerebral Adrenoleukodystrophy (CALD)
Interventions: Lenti-D Drug Product (eli-cel); Genetic
Lead sponsor: Genetix Biotherapeutics Inc.; Industry
Eligibility: Up to 17 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • Minneapolis, Minnesota

Conditions: HIV Infections
Interventions: Indinavir sulfate, Amprenavir, Nevirapine, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 12
States / cities: Los Angeles, California • Denver, Colorado • Miami, Florida + 8 more

Conditions: Postsurgical Hypothyroidism, Hypothyroidism
Interventions: thyroidectomy, levothyroxine in thyroidectomy patients; Procedure · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Urinary Incontinence
Interventions: Patient Education, Nurse Navigation, ChatBot; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV, Stimulant Use Disorder, Justice Involved Populations, HIV Prevention
Interventions: DynamiCare, Patient Navigation (PN); Device · Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: New Haven, Connecticut • Dallas, Texas

Conditions: Fertility
Interventions: Self administration; Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Fort Myers, Florida • Tampa, Florida

Conditions: Fibromyalgia
Interventions: TNX-102 SL, Placebo SL Tablet; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 33 more

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: San Francisco, California • Miami, Florida • Boston, Massachusetts + 1 more

Conditions: Small Cell Lung Cancer
Interventions: Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI); Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 35
States / cities: Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more

Conditions: Giant Cell Arteritis
Interventions: Sirukumab, Placebo to match sirukumab, Prednisone, Placebo to match prednisone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 13
States / cities: Aurora, Colorado • Boca Raton, Florida • Naples, Florida + 9 more

Conditions: Bacterial Infection
Interventions: ceftaroline, linezolid, Aztreonam; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 13
States / cities: Buena Park, California • Long Beach, California • Los Angeles, California + 10 more

Conditions: Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
Interventions: NKX101 - CAR NK cell therapy; Biological
Lead sponsor: Nkarta, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2039
U.S. locations: 8
States / cities: Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more

Conditions: Heart Defects, Congenital, Hyperglycemia
Interventions: Insulin, Usual Care; Drug · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 36 Months
Enrollment: 989 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts • Ann Arbor, Michigan

Conditions: Nephrotic Syndrome, Proteinuria
Interventions: apixaban; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 79 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Phenylketonuria, PKU
Interventions: RDD to Palynziq; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chevy Chase, Maryland

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Interferon alfa-2a, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 9
States / cities: Miami, Florida • Baltimore, Maryland • Boston, Massachusetts + 6 more

Conditions: CYP2D6 Polymorphism
Interventions: Isotretinoin, dextromethorphan; Drug
Lead sponsor: University of Washington; Other
Eligibility: 12 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sickle Cell Disease
Interventions: Propranolol, Placebo; Drug
Lead sponsor: Laura M. De Castro, MD; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: XIAP Deficiency, NLRC4-MAS
Interventions: Tadekinig alfa; Drug
Lead sponsor: AB2 Bio Ltd.; Industry
Eligibility: Not listed
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: La Jolla, California • Gainsville, Florida • Atlanta, Georgia + 5 more

Conditions: Non Small Cell Lung Cancer
Interventions: Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Rosuvastatin, Pharmacokinetic sampling - rosuvastatin, Pharmacokinetic sampling - AZ5140 and AZ7550; Procedure · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Fairfax, Virginia

Search by objective public record fields.

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer

Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV

A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir

Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?

Improving Care for Women With Urinary Incontinence (EMPOWER)

RESTORE Study R61 Phase: Recovery and Engagement for Stimulant Users on Re-entry

Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate

A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

SPECS: Safe Pediatric Euglycemia in Cardiac Surgery

Pharmacokinetics of Apixaban in Nephrotic Syndrome

Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq

Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma

Effects of Isotretinoin on CYP2D6 Activity

Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD)

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension

Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer